With a 5-year average revenue growth rate of 13.52%, Boston Scientific Corporation (NASDAQ:BSX) is included among the 11 Best Long Term US Stocks to Buy Right Now.
On May 19, Baird lowered its price recommendation on Boston Scientific Corporation (NASDAQ:BSX) to $75 from $78
It reiterated an Outperform rating on the shares. The firm updated its model after Boston Scientific re-entered the TAVR market through its stake in MiRus. Baird said the move is expected to provide modest accretion.
On May 18, BofA lowered its price goal on BSX to $68 from $105 and kept a Buy rating on the stock. The change followed meetings with 34 medtech companies in Las Vegas last week. The analyst said the firm updated several price targets to reflect what it called “the new reality of medtech valuations” amid a slower product cycle environment, concerns around the ACA and healthcare utilization, rising inflation after the war, and investor focus shifting toward “data centers over healthcare.” Also on May 18, Boston Scientific announced a $2 billion accelerated share repurchase agreement with JPMorgan Chase Bank as part of its existing $5 billion buyback program.